IngredientsFamily: Fabaceae (also referenced as Caesalpiniaceae); Genus: Campsiandra; Species: angustifolia. Common names include huacapurana, acapurana, acapu-do-igapo, apikara, caacapoc, cumandá, and gapo. The primary plant part used medicinally is the bark.
The full accepted scientific binomial is Campsiandra angustifolia Spruce ex Benth., a tree growing in the tropical forests of the Peruvian Amazon. The species was first formally described by George Bentham (1800–1884), as indicated by the abbreviation "Benth." following the name. The native range of this species is South Tropical America; it is a tree that grows primarily in the wet tropical biome, and it is used both as a medicine and for food.
According to the Colombian Plants database (drawing on Kew's Plants of the World Online), the accepted distribution of Campsiandra angustifolia encompasses Bolivia, Brazil (North and West-Central), Colombia, Peru, and Venezuela.
Campsiandra angustifolia is a medium-sized tree growing up to 15 metres tall. It grows alongside rivers and streams in the Amazon Basin. All three closely related huacapurana species produce small white to pinkish flowers with red stamens, and these trees (as most Campsiandra trees) produce a large bean pod.
Campsiandra angustifolia is a common water-dispersed tree from the Peruvian Amazon. A peer-reviewed study published in PubMed analyzed the variation in dispersal and establishment structures across 535 seeds from 13 trees in three different habitats, contributing to understanding of the species' ecology and seed biology.
The Peruvian common name huacapurana can apply to three different closely related species of Amazonian trees that are used interchangeably by local inhabitants: Campsiandra angustifolia, Campsiandra comosa, and Campsiandra laurifolia. When used in Peruvian herbal medicine, the "authentic huacapurana" is considered to be Campsiandra angustifolia. Campsiandra laurifolia is now viewed as a sub-species of Campsiandra comosa, as Campsiandra comosa laurifolia (Benth.) R.S. Cowan. This nomenclatural complexity means that some historical ethnobotanical and phytochemical literature pertaining to "huacapurana" may describe any of the three interchangeable species, and careful species-level attribution is warranted when interpreting research findings.
Two accepted infraspecific taxa are recognized: Campsiandra angustifolia var. angustifolia and Campsiandra angustifolia var. rosea (Poepp.) Stergios.
Campsiandra angustifolia is a plant native to the Amazon basin, traditionally utilized by indigenous communities for its potential health-promoting properties. Commonly known in some sources as "palo de ajo" due to its distinctive garlic-like scent, it is a leguminous plant whose bark, leaves, and roots have been used by traditional healers in South America to prepare remedies addressing a variety of health concerns.
The seed is a staple food of the Pumé Amerindian group in Apure State, Venezuela. The mature seeds are taken out of their seedpods and then buried for some time in damp soil; after a certain degree of fermentation has set in, they are dug up, washed, and then pounded into a flour rich in starch, which is used for making bread and other foods. This flour is commonly referred to as "chigo-flour."
Huacapurana is a common remedy for malarial fever in the Peruvian Amazon. In the Iquitos region, local herbalists and curanderos recommend a decoction or a tincture of the bark to be taken twice daily to reduce the fever related to malaria.
The bark is also recommended for treating other feverish conditions, arthritis and rheumatism, diarrhoea, and as a tonic. Externally, the pulverized bark is used to treat wounds and to clean sores and ulcers.
The traditional use documented in the literature encompasses the bark or the fruit, which are macerated to treat rheumatism, joint pain, fever, diarrhea, and liver illnesses.
The plant is most noted for its use in treating inflammation, digestive disturbances, and as a general tonic to strengthen the body. Its reputed anti-inflammatory and antimicrobial effects have made it a popular remedy for wounds and skin infections; in some Amazonian cultures it has been used to alleviate symptoms of malaria, fevers, and joint pain.
Traditionally, huacapurana bark is prepared as an alcoholic tincture or as a decoction. Selected Peruvian Amazon plants are also macerated into sugar cane distillates to prepare alcoholic beverages used to improve male sexual performance.
The tree bark from Campsiandra angustifolia Spruce ex Benth. (Fabaceae) is typically used as a crude drug in mixtures of several ingredients in traditional Peruvian Amazon preparations, alongside species such as Swartzia polyphylla DC. (Fabaceae), Minquartia guianensis Aubl. (Olacaceae), and Tynanthus panurensis (Bureau) Sandwith (Bignoniaceae). Two traditional preparations from Iquitos markets are known colloquially as "Levántate Lázaro" and "Siete veces sin sacarla."
The bark has been widely touted as a treatment for Lyme's Disease as well as a host of other microbial issues and diseases; however, none of these claims can be substantiated by independent third-party documentation or published research, nor even by traditional use. This commercially driven claim is distinct from the traditional antimalarial, anti-rheumatic, and digestive applications documented by ethnobotanists in Peru.
Preliminary studies have focused on the phytochemical profile of Campsiandra angustifolia, revealing the presence of bioactive compounds such as flavonoids, saponins, and tannins. These findings have been corroborated by independent phytochemical screening: a study by Flores et al. showed a positive result for the presence of flavonoids, saponins, and tannins in the hulls (bark) of C. angustifolia.
The most detailed published phytochemical analysis of C. angustifolia bark comes from a 2018 peer-reviewed study in the Journal of Ethnopharmacology (published on ScienceDirect). Chemical profiling of that study allowed the identification of condensed tannins as the main constituents of C. angustifolia. More specifically, the chemical profile of C. angustifolia shows mainly proanthocyanidins and gallotannins, flavonoids, and caffeoylquinic acid. The study reported for the first time the chemical composition of the crude drug C. angustifolia in this context.
A total of 31 compounds were detected in C. angustifolia in that analysis, making it the most comprehensively profiled of the four plants studied in that work.
Phytochemical investigation has revealed the presence of flavonoids, saponins, and tannins; these constituents are known for their antioxidant and anti-inflammatory properties in other botanicals, suggesting potential mechanisms for the plant's traditional uses. The concurrent presence of caffeoylquinic acids, which are phenolic esters with recognized antioxidant properties, further broadens the polyphenolic profile of the bark.
The most rigorously documented mechanistic finding for C. angustifolia comes from in vitro enzyme inhibition assays. From the crude drugs tested, high activity was found for C. angustifolia, which inhibited the phosphodiesterase-5 (PDE-5) enzyme by 89.37% and 81.32% at 200 and 100 µg/mL, respectively. The authors concluded that the traditional preparations used to improve sexual performance in the Peruvian Amazon showed activity as phosphodiesterase-5 inhibitors, with C. angustifolia identified as the most active ingredient.
PDE-5 is the enzyme targeted by pharmaceutical drugs such as sildenafil (Viagra). PDE-5 inhibitors improve nitric-oxide-dependent vasodilation by preventing the breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in vascular smooth cells. The mechanism by which C. angustifolia condensed tannins and related polyphenols achieve this inhibition at the molecular level has not yet been fully characterized.
Campsiandra angustifolia Spruce ex Benth. has been cited in a broader review as among the plants proven for their PDE-5 inhibition effect.
Laboratory investigations have indicated that extracts from Campsiandra angustifolia may exhibit antioxidant activity, which could help protect cells from oxidative stress. This activity is consistent with the high polyphenol and tannin content documented in phytochemical screening, as tannins and proanthocyanidins are broadly recognized free-radical scavengers.
Some laboratory investigations have indicated that extracts from Campsiandra angustifolia may exhibit antioxidant activity and possible antimicrobial and immunomodulatory effects, although these findings have yet to be confirmed in large-scale human trials.
Study type and specifics: The key peer-reviewed evidence is a 2018 in vitro laboratory study published in the Journal of Ethnopharmacology (PMID 30339977). The researchers purchased crude drugs from the Mercado Belen market in Iquitos, Peru. The presence of pro-sexual pharmaceutical drugs such as sildenafil and derivatives was assessed in the samples to rule out adulteration. No adulterations with pro-sexual drugs were found in the samples. PDE-5 enzyme inhibition was then quantified across a concentration range. At 200 µg/mL, the traditional preparation "Levántate Lázaro" and "Siete veces sin sacarla" inhibited phosphodiesterase-5 by 49.88% and 27.90%, respectively.
Limitations and evidence strength: The authors acknowledged that these results encourage additional studies, including animal models, to confirm the male enhancer effect of the preparations. All evidence is in vitro only; no animal studies or human clinical trials have been published for this specific endpoint. The overall evidence grade is preliminary (in vitro, preclinical only).
The use of C. angustifolia bark decoction or tincture as an antimalarial remedy in the Iquitos region of Peru is well documented in ethnobotanical literature. However, no peer-reviewed pharmacological or clinical studies have validated anti-plasmodial activity specifically for C. angustifolia. The evidence remains at the level of traditional practice and ethnographic documentation.
The attribution of anti-inflammatory properties to C. angustifolia is based entirely on traditional use and is extrapolated from the known properties of its constituent compound classes (tannins, flavonoids). No in vitro, animal, or human studies specifically assessing anti-inflammatory endpoints for C. angustifolia bark extracts have been identified in the peer-reviewed literature. Evidence is therefore classified as traditional/theoretical only.
Laboratory-level evidence exists: however, direct clinical evidence supporting specific health outcomes in humans remains limited; some laboratory investigations have indicated that extracts may exhibit antioxidant activity, which could help protect cells from oxidative stress. These are preliminary in vitro findings and have not been tested in human populations.
In vitro studies suggest possible antimicrobial and immunomodulatory effects, although these findings have yet to be confirmed in large-scale human trials. The condensed tannins identified as dominant constituents of the bark are themselves a class of compounds recognized in the broader phytochemical literature for protein-binding properties that can disrupt microbial membranes, though species-specific antimicrobial studies for C. angustifolia remain scarce and unpublished in indexed databases at the time of writing.
One of the prominent traditional applications involves decoctions or infusions of the bark to ease stomach complaints such as diarrhea and dysentery. No clinical studies have evaluated this indication.
Based on documented traditional use and the preliminary in vitro data available, Campsiandra angustifolia is associated with the following body systems:
In herbal combinations, Campsiandra angustifolia is often blended with other Amazonian botanicals such as Uncaria tomentosa (cat's claw) and Tabebuia impetiginosa (pau d'arco).
Campsiandra angustifolia bark is currently available in international supplement markets primarily as an alcoholic liquid tincture (bark extract). Formulations typically use bark as the sole medicinal ingredient, extracted in a hydroalcoholic base.
One commercial tincture product profile describes: bark (part used), 50% alcohol content, herb:menstruum ratio 1:4, produced by whole-herb percolation extraction.
The following dosage ranges appear in product documentation (these are manufacturer-stated dosages, not those from controlled human studies):
In the in vitro PDE-5 study, crude extracts from stem and roots were evaluated in concentrations ranging from 0–500 µg/mL. These are laboratory assay concentrations and do not correspond to human dosing recommendations.
No human clinical pharmacokinetic or dose-finding studies for C. angustifolia have been published in indexed literature.
According to the Tropical Plant Database (Leslie Taylor, 2006), no contraindications and no drug interactions are known for huacapurana bark.
Commercial tincture products caution against use in pregnancy and lactation: one product states "do not use this product if you are pregnant or breastfeeding." No published toxicological data substantiates or quantifies this risk; the contraindication appears to be a precautionary standard applied to all botanical extracts with insufficient safety data.
No formal toxicological studies (acute toxicity, chronic toxicity, genotoxicity, or reproductive toxicity) for Campsiandra angustifolia bark extracts have been identified in indexed peer-reviewed databases. Direct clinical evidence supporting specific health outcomes in humans remains limited. More rigorous clinical research is needed to validate its efficacy and safety in nutritional products.
Currently, at least one product available in the U.S. market for huacapurana has been widely touted for Lyme's Disease as well as a host of other microbial issues and diseases, yet none of these claims can be substantiated by independent third-party documentation or published research, nor even by traditional use. The marketing of this botanical for unvalidated and potentially serious infectious diseases raises concerns about patient safety that are independent of the plant's intrinsic toxicological profile.
The dominant constituents of C. angustifolia bark are condensed tannins. While tannins as a class are not acutely toxic at dietary concentrations, very high chronic tannin intake from herbal preparations has been associated in the broader phytochemical literature with protein precipitation and potential impact on nutrient absorption (particularly iron and protein bioavailability). No specific data quantifying this risk for C. angustifolia preparations has been published.
Given the documented in vitro PDE-5 inhibitory activity, theoretical pharmacodynamic interactions with pharmaceutical PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) are plausible. This interaction has not been studied in humans, but additive vasodilatory effects are a theoretical concern.
Health conditions that Campsiandra angustifolia may help support.
Body systems that Campsiandra angustifolia may help support.
Go back